Complement receptor type two (CR2,CR21): a target for influencing the humoral immune response and antigen-trapping.
Cellular receptors for complement C3 fragments deposited on antigens are important bricks in the wall defending against microbial pathogens. The part of complement receptor type 2 (CR2; CD21) deals with enhancing humoral immune responses and with long-term trapping of C3d-coated antigen by follicular dendritic cells. CR2 is also pivotal for Epstein-Barr virus (EBV) infection. Here, the current understanding, how CR2 interacts with its ligands C3d, EBV, and CD23 is summarized. The potential to target CR2 for clinical therapy or immunization purposes are discussed.
Prodinger
W M
WM
Institut für Hygiene, University of Innsbruck, Austria. wolfgang.prodinger@uibk.ac.at
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000627:therapeutic use; D000917:Antibody Formation; D001402:B-Lymphocytes / Q000378:metabolism; D001665:Binding Sites; D015933:Complement C3d / Q000378:metabolism; D020566:Dendritic Cells, Follicular / Q000378:metabolism; D006801:Humans; D051379:Mice; D011323:Primates; D017464:Receptors, Complement 3d / Q000737:chemistry / Q000276:immunology* / Q000378:metabolism; D017455:Receptors, IgE / Q000378:metabolism / Q000627:therapeutic use; D014763:Viral Matrix Proteins / Q000378:metabolism
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; C037662:EBV-associated membrane antigen, Epstein-Barr virus; D017464:Receptors, Complement 3d; D017455:Receptors, IgE; D014763:Viral Matrix Proteins; D015933:Complement C3d